Apr
30
Posted under
AstraZeneca,
Biotech CEO,
Blog,
Chutes and Ladders,
Companies,
David Brennan,
Diagnostics,
Funding,
Medical Devices,
Medical Supply,
Pharmaceuticals,
Startups,
Universities,
Videos by john
As usual with pharma CEO departures, the first wave of talk is all about the simple facts--who and how and why. Next? The gossip about severance. In David Brennan's case, word is that he's due for a golden handshake of up to £40 million, or $65 million, from AstraZeneca ($AZN). Story
Dec
14
Posted under
Biotech CEO,
Blog,
Companies,
Diagnostics,
Funding,
Hepatitis C,
Incivek,
Matthew Emmens,
Medical Devices,
Medical Supply,
Pharmaceuticals,
Pharmasset,
Startups,
Universities,
vertex,
Videos by John Carroll
Who's the best CEO in biotech? TheStreet posed that question to its readers and came up with Matthew Emmens, who helms Vertex ($VRTX). Vertex has had a big year, of course, with the successful launch of Incivek, the new standard of care for hepatitis C. But no sooner had that treatment hit the market than analysts turned to the pipeline looking for the next-gen program most likely to achieve success, and that persuaded TheStreet's Adam Feuerstein to declare that Pharmasset CEO Schaefer Price was even more deserving of recognition after orchestrating an $11 billion buyout deal with Gilead. Of course, Gilead CEO John Martin was also nominated by Feuerstein as one of the worst CEOs of the year. (Mitch Gold at Dendreon won that vote.) Maybe opposites attract in this business. Story
Dec
09
Posted under
Biotech CEO,
Blog,
Companies,
Dendreon,
Diagnostics,
Funding,
Medical Devices,
Medical Supply,
Pharmaceuticals,
Provenge,
Startups,
Universities,
Videos by Ryan McBride
Mitch Gold and his struggling biotech Dendreon ($DNDN) can't catch a break since disappointing Wall Street with lackluster sales of the prostate cancer drug Provenge. TheStreet announced Gold was voted this year's worst chief executive in a poll that drew 1,800 votes. It's more proof of how a disappointing drug launch can quickly change the fortunes of a biotech CEO; Gold was voted as TheStreet's best chief last year after his company gained the first-ever FDA nod for a cancer vaccine. Article